Cargando…

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease

Generation of reactive oxygen species during dopamine (DA) oxidation could be one of the factors leading to the selective loss of nigral dopaminergic neurons in Parkinson’s disease (PD). Vesicular monoamine transporter type 2 (VMAT2) proteins in nerve terminals uptake dopamine into synaptic vesicles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brighina, Laura, Riva, Chiara, Bertola, Francesca, Saracchi, Enrico, Fermi, Silvia, Goldwurm, Stefano, Ferrarese, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Genetic Reports Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605583/ https://www.ncbi.nlm.nih.gov/pubmed/23369548 http://dx.doi.org/10.1016/j.neurobiolaging.2012.12.020

Ejemplares similares

Association analysis of PARP1 polymorphisms with Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2011)

The ins and outs of vesicular monoamine transporters
por: Yaffe, Dana, et al.
Publicado: (2018)

Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men
por: Yang, Xinglong, et al.
Publicado: (2015)

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
por: Caroff, Stanley N.
Publicado: (2020)

Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism
por: Beauchamp, Leah C., et al.
Publicado: (2020)

Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson
por: Pifl, Christian, et al.
Publicado: (2023)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019)

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions
por: Alwindi, Malik, et al.
Publicado: (2023)

No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease
por: Tian, LinLin, et al.
Publicado: (2012)

An Acidic Motif Retains Vesicular Monoamine Transporter 2 on Large Dense Core Vesicles
por: Waites, Clarissa L., et al.
Publicado: (2001)

Differential Localization of Vesicular Acetylcholine and Monoamine Transporters in PC12 Cells but Not CHO Cells
por: Liu, Yongjian, et al.
Publicado: (1997)

VTP-Identifier: Vesicular Transport Proteins Identification Based on PSSM Profiles and XGBoost
por: Gong, Yue, et al.
Publicado: (2022)

A Glial Variant of the Vesicular Monoamine Transporter Is Required To Store Histamine in the Drosophila Visual System
por: Romero-Calderón, Rafael, et al.
Publicado: (2008)

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells
Publicado: (1994)

Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing
por: Lohoff, Falk W., et al.
Publicado: (2013)

Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice
por: Baumann, Aron, et al.
Publicado: (2016)

A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders
por: NIKKHAH, Ali
Publicado: (2021)

Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics
por: Abak, Atefe, et al.
Publicado: (2018)

Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas
por: Saisho, Yoshifumi, et al.
Publicado: (2008)

Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population
por: Richards, Misty, et al.
Publicado: (2006)

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2
por: Huang, Zih-Rou, et al.
Publicado: (2016)

An association study between various monoamine transporter gene polymorphisms and treatment response to mirtazapine in major depression
por: Choi, Hong
Publicado: (2010)

Tyrosine Hydroxylase, Vesicular Monoamine Transporter and Dopamine Transporter mRNA Expression in Nigrostriatal Tissue of Rats with Pedunculopontine Neurotoxic Lesion
por: Blanco-Lezcano, Lisette, et al.
Publicado: (2018)

Elevated Levels of the Vesicular Monoamine Transporter and a Novel Repetitive Behavior in the Drosophila Model of Fragile X Syndrome
por: Tauber, John M., et al.
Publicado: (2011)

Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats
por: Hiranita, Takato
Publicado: (2015)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET
por: Lin, Kun-Ju, et al.
Publicado: (2013)

Precise CRISPR-Cas9-mediated mutation of a membrane trafficking domain in the Drosophila vesicular monoamine transporter gene
por: Asuncion, James D., et al.
Publicado: (2023)

Elucidating the Relationship Between Diabetes Mellitus and Parkinson’s Disease Using (18)F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2
por: Kong, Yanyan, et al.
Publicado: (2020)

Improved Working Memory but No Effect on Striatal Vesicular Monoamine Transporter Type 2 after Omega-3 Polyunsaturated Fatty Acid Supplementation
por: Narendran, Rajesh, et al.
Publicado: (2012)

Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas
por: Freeby, Matthew, et al.
Publicado: (2012)

Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens
por: David, H N, et al.
Publicado: (2015)

A mini-review of the role of vesicular glutamate transporters in Parkinson’s disease
por: Zhao, Cheng, et al.
Publicado: (2023)

Monoamine oxidase a gene polymorphism associated with hostility in male population of 45-64 in Russia/Siberia
por: Gafarov, V., et al.
Publicado: (2021)

Polymorphisms in Manganese Transporters SLC30A10 and SLC39A8 Are Associated With Children's Neurodevelopment by Influencing Manganese Homeostasis
por: Wahlberg, Karin E., et al.
Publicado: (2018)

Rotenone Upregulates Alpha-Synuclein and Myocyte Enhancer Factor 2D Independently from Lysosomal Degradation Inhibition
por: Sala, Gessica, et al.
Publicado: (2013)

Monoamine Reuptake Inhibitors in Parkinson's Disease
por: Huot, Philippe, et al.
Publicado: (2015)

A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets
por: Padmakumar, Manisha, et al.
Publicado: (2019)

Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent
por: Jiang, Donglang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9qs3ffr88c25dgf4uau2nqk658